Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
Glucagon-like peptide-1 is a potent hypoglycemic hormone with beneficial properties for the treatment of diabetes. However, its half-life is short because the rapid metabolic degradation. This study aims to prolong the half-life of glucagon-like peptide-1 through conjugation with the fatty acid side chain which helps the conjugates to interact with the albumin. Firstly, we chose two optimized polypeptide chains which have tremendous hypoglycemic effect named Cys17-Gly8-GLP-1(7-36)-NH2 and Cys37-Gly8-GLP-1(7-37)-NH2, and various fatty acid chains were modified. All conjugates preserved relatively strong GLP-1R activation and I-6 behaved best in glucose-lowering ability. The prolonged antidiabetic effects of I-6 were further confirmed by hypoglycemic efficacy test in vivo. Meanwhile, once daily injection of I-6 to diabetic mice achieved long-term beneficial effects on glucose tolerance, body weight and blood chemistry. It is concluded that I-6 is a promising agent for further investigation of its potential to treat obese patients with diabetes.
['Cai|Xingguang|X|', 'Sun|Lidan|L|', 'Dai|Yuxuan|Y|', 'Avraham|Yosefa|Y|', 'Liu|Chunxia|C|', 'Han|Jing|J|', 'Liu|Yuan|Y|', 'Feng|Dazhi|D|', 'Huang|Wenlong|W|', 'Qian|Hai|H|']
D017667:Adipocytes D052242:Adiponectin D000818:Animals D001786:Blood Glucose D001835:Body Weight D002470:Cell Survival D004355:Drug Stability D005227:Fatty Acids D052216:Glucagon-Like Peptide 1 D057809:HEK293 Cells D006207:Half-Life D006801:Humans D007004:Hypoglycemic Agents D020738:Leptin D055666:Lipopeptides D000069450:Liraglutide D008297:Male D008810:Mice, Inbred C57BL D015394:Molecular Structure D010179:Pancreas D017207:Rats, Sprague-Dawley D000075462:Serum Albumin, Human
Fatty acid GLP-1 Diabetes Body weight